Changes in Blood Lipid Profile and Hepatic Enzyme Levels after Oriental Medical Treatment to Metabolic Syndrome Patients with Abnormal Liver Function

  • Kim, Dong-Woung (Department of Internal Medicine, College of Oriental Medicine, Wonkwang University)
  • Published : 2008.12.25

Abstract

Among patients who are receiving treatments at an oriental medical hospital for various symptoms and diseases, patients whose main disease is accompanied by metabolic syndrome with abnormal liver function. This research was performed in order to observe the progression of changes in the liver function and serum lipid profile after the oriental medical treatments to patients who have been receiving oriental medical treatment for various other diseases and have been diagnosed as having metabolic syndrome at their first visit to the hospital based on NCEP ATP III diagnosis criteria and WHO Asia Pacific region criteria. Total number of subject patients were 39cases(mean age:55.58${\pm}$2.09 years) which had 20 male and 19 female. For the references for hepatic enzyme levels and blood lipid profile were measured in before treatment and four times after treatments(every 2.31${\pm}$06.17 weeks). Serum AST was 48.86${\pm}$7.46 IU/L before oriental medical treatment. After the treatment, 40.63${\pm}$4.69, 43.12${\pm}$5.46, 37.82${\pm}$4.52 IU/L were measured where although the level decreased to the normal level compared to pre-treatment, the value was not significant statistically(P>0.05). ALT was 66.26${\pm}$11.01 IU/L before oriental medical treatment. After the treatment 62.10${\pm}$8.20, 61.10${\pm}$8.76, 43.79${\pm}$5.68 were measured where although the level decreased, abnormally high level was maintained. The last result was significant statistically(P<0.05) compared to pre-treatment. ALP was 193.06${\pm}$14.20 IU/L before oriental medical treatment. After the treatment, 176.80${\pm}$6.48, 177.46${\pm}$11.81, 162.41${\pm}$9.06 where although compared to pre-treatment the last result was significant statistically(P<0.05), the change was within the normal range. ${\gamma}$-GGT was 87.83${\pm}$12.59 IU/L before oriental medical treatment. After the treatment, progressively near normal level was achieved with 118.73${\pm}$46.45, 85.03${\pm}$17.12, 70.64${\pm}$10.93 and the last result was statistically significant compared to pre-treatment (P<0.05). Blood triglyceride was 217.63${\pm}$32.18 mg/dL before oriental medical treatment. After treatment 215.09${\pm}$22.18, 189.93${\pm}$22.44, 191.22${\pm}$18.51 where abnormal values continued even after treatment although results was not statistically significant compared to pre-treatment(P>0.05). Total-cholesterol was 197.28${\pm}$9.24 mg/dL before oriental medical treatment, after treatment 201.55${\pm}$11.13, 186.87${\pm}$8.77 and 186.68${\pm}$7.61 were measured that results were not statistically significant compared to pre-treatment(P>0.05). HDL-cholesterol was 41.88${\pm}$2.38 mg/dL before oriental medical treatment, after treatment 48.75${\pm}$4.22, 44.10${\pm}$1.91, 48.00${\pm}$2.06 the results were not statistically significant compared to pre-treatment(P>0.05). LDL-cholesterol was 111.66${\pm}$13.08 mg/dL before oriental medical treatment, after treatment 109.94${\pm}$10.18, 101.79${\pm}$8.63, 104.00${\pm}$6.98 the results were not statistically significant compared to pre-treatment(P>0.05). With such results, even if common oriental medical treatments were given to metabolic syndrome patients with abnormal liver function, the liver function was confirmed not to be aggravated, and the concentration of lipids in the blood was confirmed not to be affected in most patients.

References

  1. Isoma, B., Almgren, P., Tuomi, T. Cardiovascular morbidity associated with the metabolic syndrome. Diabetes Care 24: 683-689, 2001. https://doi.org/10.2337/diacare.24.4.683
  2. Kang, H., Greenson, J.K., Omo, J.T., Chao, C., Peterman, D., Anderson, L., Foess-Wood, L., Sherbondy, M.A., Conjeevaram, H.S. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol 101: 2247-2253, 2006. https://doi.org/10.1111/j.1572-0241.2006.00719.x
  3. Ludwing, J., Viggiano, T.R., McGill, D.B., Oh, B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with an hitherto unnamed disease. Mayo Clin Proc 55: 434-438, 1980.
  4. D.W. Kim, L.J. Lee, I.H. An, J.S. Ban, C.Y. Rheu, S.M. Kim, S.M. Lee. The change of liver function in patients with long term herb medication by frequently prescribed formular. J of Korean Oriental Medicine 14(2):245-253, 1993.
  5. Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M. et al. Nonacoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50(8):1844-1850, 2001. https://doi.org/10.2337/diabetes.50.8.1844
  6. Lee, D.H., Steffen, L.M., Jacobs, D.R. Jr., Association between serum ${\gamma}$-glutamyltransferase and diatary factors: The coronary artery risk development in young adults (CARDIA) study. Am J Clin Nutr 79: 600-605, 2004. https://doi.org/10.1093/ajcn/79.4.600
  7. K.W. Moon., J.M. Leem., S.S. Bae., K.M. Lee., S.H. kim., H.B. Chae., S.M. Park., S.J. Youn. The prevalence of Metabolic Syndrome in Patients with Nonalcoholic Fatty Liver Disease. Korean J Hepatol 10(3):197-206, 2004.
  8. Lewis G.F., Steiner, G. Acute effects of insulin in the control of VLDL production in humans. Implications for insulin-resistance state. Diabetes Care 19: 390-393, 1996. https://doi.org/10.2337/diacare.19.4.390
  9. International Obesity Task Force. The Asia-Pacific perspective: Redefining obesity and its treatment. Western Pacific Region. 2000.
  10. H.S. Park, S.W. OH, J.H. Kang, Y.W. Park, J.M. Choi, Y.S. Kim, W.H. Choi, H.J. Yoo, Y.S. Kim. Prevalence and associated factors with metabolic syndrome in south korea (-from the korean national health and nutrition examination survay, 1998-) Korean J of Obesity. 12(1):1-14, 2003.
  11. H.J. Lee, H.S. Kwon, Y.M. Park, H.N. Chun, Y.H. Choi, S.H. Ko, J.M. Lee, K.H. Yoon, B.Y. Cha, W.C. Lee, K.W. Lee, H.Y. Son, S.K. Kang, M.S. Ahn, J.M. Kang, D.S. Kim. Waist circumference as a risk factor for metabolic syndrome in korean adult ; evaluation from 5 different criteria of metabolic syndrome. J Kor Diabetes Assoc 29: 48-56, 2005.
  12. S.M. Nam., H.Y. Yu., M.Y. Lee., J.H. Koh., J.Y.l. Shin., Y.G. Shin., C.H. Chung. Alcohol Consumption, Liver Enzymes, and Prevalence of Metabolic Syndrome in Korean Adult Men, Kor Diabetes Assoc 31(3):253-260, 2007. https://doi.org/10.4093/jkda.2007.31.3.253
  13. Steiner, G., Altering triglyceride concentrations changes insulin-glucose relationships in hypertriglyceridemic patients. Double blind study with gemfibrozil with implications for lipoproteins. Curr Opin lipidol 4: 252-257, 1994.
  14. Facchini, F.S., Hua, N., Abbasi, F., Reaven, G.M. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 86: 3574-3578, 2001. https://doi.org/10.1210/jc.86.8.3574
  15. Yip, J., Facchini, F.S., Reaven, G.M. Resistance to insulin mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 83: 2773-2776, 1998. https://doi.org/10.1210/jc.83.8.2773
  16. Angulo, P. Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231, 2002. https://doi.org/10.1056/NEJMra011775
  17. Liese, A.D., Mayer-Davis, E.J., Tyroler, H.A., Davis, C.E., Keil, U., Schmit, M.I., Brancati, F.L., Heiss, G. Familial components of the multiple metabolic syndrome: The ARIC study. Diabetologia 40: 963-970, 1997. https://doi.org/10.1007/s001250050775
  18. Executive Summary of the Third Report of the National Cholesterol Education Program(NCEP) Expert Panel on Detection, Evaluation, and treatment of high blood cholesterol in adults(Adult Treatment Pannel III). JAMA 28: 2486-2497, 2001.
  19. Herbert, Jr. L.F., Daniels, M.C., Zhou, J., Crook, E.D., Turner, R.L., Simmons, S.T., Neidigh, J.L., Zhu, J.S., Baron, A.D., McClain, D.A. Over-expression of glutamine: fructose-6 phosphate aminotransferase in transgenic mice leads to insulin resistance. J Clin Invest 98: 930-936, 1996. https://doi.org/10.1172/JCI118876
  20. Reaven, G.M. Role of insuline resistance in human disease. diabetes 37: 1595-1607, 1988. https://doi.org/10.2337/diabetes.37.12.1595
  21. Hong, Y., Pedersen, N.L., Brismar, K., De Faire, U. Genetic and environmental architecture of the features of the insulin-resistance sydrome. Am J Hum Genet 60: 143-152, 1997.
  22. Dong Woung Kim, Kwan Sik Kim. The clinical study of long term herb medication in the B viral hepatitis health carrier, Korean J. Oriental Medical Pathology 13(2):128-133, 1999.
  23. Contos, M.J., Sanyal, A.J. The clinicopathologic spectrum and management of nonalcoholic fatty liver disease. Adv Anat pathol 9: 37-51, 2002. https://doi.org/10.1097/00125480-200201000-00005
  24. Lim, J.S., Yang, J.H., Chun, B.Y., Kam, S., Jacobs, D.R. Jr., Lee, D.H. Is serum ${\gamma}$-glutamyltransferase inversely associated with serum antioxidants as a marker of oxidative stress? Free Radic Biol Med 37: 1018-1023, 2004. https://doi.org/10.1016/j.freeradbiomed.2004.06.032
  25. Saito, T., Misawa, K., Kawata, S. Fatty liver and non-alcoholic steatohepatitis. Inter Med 46: 101-103, 2007. https://doi.org/10.2169/internalmedicine.46.1784
  26. Bjorntorp, P. portal adipose tissue as a generator of risk factors for cardiovascular disease and diabetes(editorial). Atherosclerosis 10: 493-496, 1990.
  27. Lee, D.H., Ha, M.H., Kim, J.H., Christiani, D.C., Gross, M.D., Steffes, M., Blomhoff, R., Jacobs, D.R. ${\gamma}$- glutamyltransdferase and diabetes- a 4 year follow -up study. Diabetologia 46: 359-364, 2003. https://doi.org/10.1007/s00125-003-1036-5